🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 160 of 857 · Phase 3 first, then by program name

  1. Ritlecitinib tosilate, Placebo to match ritlecitinib 50 mg, Ritlecitinib, Placebo to match ritlecitinib 30 mg

    Pfizer Australia Pty Ltd

    Alopecia areata

    phase 3 small molecule active

    1 trial

  2. Ritlecitinib tosilate, Ritlecitinib Tosilate

    Pfizer Australia Pty Ltd

    Alopecia areata

    phase 3 small molecule active

    1 trial

  3. Rituximab

    The First People's Hospital of Lianyungang

    Refractory Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  4. Rituximab

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    3 trials

  5. Rituximab

    Janssen Cilag International NV

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    1 trial

  6. Rituximab

    Hospital Authority, Hong Kong

    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    phase 3 mab completed

    1 trial

  7. Rituximab

    United Therapeutics Europe Ltd

    Follicular Lymphoma

    phase 3 small molecule completed

    1 trial

  8. Rituximab

    Lxo Ireland Designated Activity Company

    Lupus Nephritis

    phase 3 mab terminated

    1 trial

  9. Rituximab

    United Therapeutics Europe Ltd

    Kidney Transplant Rejection

    phase 3 small molecule terminated

    1 trial

  10. Rituximab (RTX)

    Incyte

    Diffuse Large B-cell Lymphoma

    phase 3 small molecule completed

    1 trial

  11. Rituximab 375 mg/m^2

    Takeda

    Mantle Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  12. Rivaroxaban

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  13. Rivaroxaban (Xarelto, BAY59-7939)

    Bayer HealthCare AG

    Venous Thromboembolism

    phase 3 small molecule completed

    2 trials

  14. Rivaroxaban (Xarelto, BAY59-7939)

    Bayer HealthCare AG

    Prevention & Control

    phase 3 small molecule completed

    1 trial

  15. Rivaroxaban (Xarelto, BAY59-7939)

    Bayer HealthCare AG

    Pulmonary Embolism

    phase 3 small molecule completed

    1 trial

  16. Rivaroxaban 2.5 Mg Oral Tablet

    The George Institute

    Chronic Kidney Diseases

    phase 3 small molecule completed

    1 trial

  17. Rivaroxaban 2.5 mg

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Acute Coronary Syndrome

    phase 3 small molecule completed

    1 trial

  18. Rivastigmine Transdermal System

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 3 small molecule completed

    1 trial

  19. RoActemra 20 mg/mL concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Neulasta 6 mg solution for injection, AZD0486, RoActemra 20 mg/mL concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Ribodoxo® 2 mg/ml Injektionslösung, Prednison 20 mg GALEN®, AZD0486, Endoxan 500 mg, poeder voor oplossing voor injectie, Ruxience 500 mg concentrate for solution for infusion

    AstraZeneca AB

    Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  20. RoActemra 20 mg/mL concentrate for solution for infusion, Tofidence 20 mg/mL concentrate for solution for infusion, Avtozma 20 mg/mL concentrate for solution for infusion., SODIUM CHLORIDE, Tyenne 20 mg/ml concentrate for solution for infusion

    Pari Pharma GmbH

    Chondrocalcinosis

    phase 3 small molecule active

    1 trial

  21. Robotic Gastrectomy

    The First People's Hospital of Lianyungang

    Gastric Cancer (GC)

    phase 3 other active

    1 trial

  22. Rocatinlimab, Placebo for AMG 451

    Amgen

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  23. Roflumilast

    AstraZeneca

    Asthma

    phase 3 small molecule completed

    1 trial

  24. Roflumilast

    AstraZeneca

    COPD

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources